Patents by Inventor Chad Anthony Dickey

Chad Anthony Dickey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GRP94 selective inhibitors and uses thereof
    Patent number: 11939291
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: March 26, 2024
    Assignees: University of Kansas, University of South Florida
    Inventors: Sanket Jaiprakash Mishra, Brian S. J. Blagg, Chad Anthony Dickey
  • GRP94 SELECTIVE INHIBITORS AND USES THEREOF
    Publication number: 20220024869
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Application
    Filed: April 9, 2021
    Publication date: January 27, 2022
    Inventors: Sanket Jaiprakash Mishra, Brian S.J. Blagg, Chad Anthony Dickey
  • Grp94 selective inhibitors and uses thereof
    Patent number: 10975030
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 13, 2021
    Assignees: University of Kansas, University of South Florida
    Inventors: Sanket Jaiprakash Mishra, Brian S. J. Blagg, Chad Anthony Dickey
  • GRP94 SELECTIVE INHIBITORS AND USES THEREOF
    Publication number: 20200071271
    Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
    Type: Application
    Filed: October 31, 2017
    Publication date: March 5, 2020
    Inventors: Sanket Jaiprakash MISHRA, Brian S.J. BLAGG, Chad Anthony DICKEY
  • Compositions and methods of treatment for myocilin glaucoma by selectively inhibiting GRP94
    Patent number: 9045434
    Abstract: A compound and method for treating myocilin glaucoma using a selective Grp94 inhibitor is presented. Clearance of mutant myocilin can be promoted by selectively targeting the endoplasmic reticulum (ER) chaperone Grp94 using siRNA knockdown or small molecule inhibitors. Grp94 contributes to the intracellular accumulation of mutant myocilin. Tailored treatments aimed at disrupting the Grp94/mutant myocilin interaction can be used as a new therapeutic strategy for myocilin glaucoma. The inventors developed a compound having a general backbone structure of geldanamycin (GDA) and radicicol (RDC) in which a more hydrophobic surrogate of the quinone in GDA is linked to the resorcinol in RDC through a cis-amide bioisostere.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: June 2, 2015
    Assignees: University of South Florida, The University of Kansas
    Inventors: Chad Anthony Dickey, Amirthaa Suntharalingam, Brian S. J. Blagg